Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3

被引:0
|
作者
Stéphane Califice
Vincent Castronovo
Marc Bracke
Frédéric van den Brûle
机构
[1] Metastasis Research Laboratory,Department of Radiotherapy and Nuclear Medicine
[2] Experimental Cancer Research Center,Department of Gynecology
[3] University of Liège,undefined
[4] Laboratory of Experimental Cancerology,undefined
[5] Ghent University Hospital,undefined
[6] University of Liège,undefined
来源
Oncogene | 2004年 / 23卷
关键词
galectin-3; prostate cancer; nucleus; cytoplasm;
D O I
暂无
中图分类号
学科分类号
摘要
Galectin-3, a multifunctional lectin, is involved during cancer progression. Previous observations showed that both cytosolic expression and nuclear exclusion of galectin-3 in human prostate cancer cells were associated to progression of the disease. In this study, we examined the biological roles of galectin-3 when expressed either in the nucleus or in the cytosol. LNCaP, a galectin-3-negative human prostate cancer cell line, was used to generate transfectants expressing galectin-3 either in the nucleus or in the cytosol. No changes in cell morphology, proliferation, attachment to laminin-1 or androgen dependency were observed. Cytoplasmic galectin-3 induced significantly increased Matrigel invasion, anchorage-independent growth and in vivo tumor growth and angiogenesis, and decreased inducible apoptosis. Surprisingly, nuclear galectin-3 affected these parameters in an opposite fashion with an overall antitumoral activity. Thus, our study demonstrates that galectin-3 exerts opposite biological activities according to its cellular localization: nuclear galectin-3 plays antitumor functions and cytoplasmic galectin-3 promotes tumor progression.
引用
收藏
页码:7527 / 7536
页数:9
相关论文
共 50 条
  • [21] Galectin-3 and metastasis
    Takenaka, Y
    Fukumori, T
    Raz, A
    GLYCOCONJUGATE JOURNAL, 2002, 19 (7-9) : 543 - 549
  • [22] Galectin-3 and metastasis
    Yukinori Takenaka
    Tomoharu Fukumori
    Avraham Raz
    Glycoconjugate Journal, 2002, 19 : 543 - 549
  • [23] Galectin-3, galectin-9, and galectin-3 binding protein in patients with inflammatory bowel diseases
    Cibor, D.
    Szczeklik, K.
    Owczarek, D.
    Mach, T.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S96 - S97
  • [24] GALECTIN-3: A USEFUL TUMOR MARKER IN THYROID AND COLORECTAL CANCER
    Ludvikova, Marie
    Holubec, Lubos, Jr.
    Kholova, Ivana
    Reischig, Josef
    Topolan, Ondrej
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3389 - 3390
  • [25] Expression of galectin-3 in the tumor immune response in colon cancer
    Dumont, Patrick
    Berton, Alix
    Nagy, Nathalie
    Sandras, Flavienne
    Tinton, Sandrine
    Demetter, Pieter
    Mascart, Francoise
    Allaoui, Abdelmounaaim
    Decaestecker, Christine
    Salmon, Isabelle
    LABORATORY INVESTIGATION, 2008, 88 (08) : 896 - 906
  • [26] Expression of galectin-3 in gastric cancer
    Nakamura, N.
    Katoh, R.
    Nagao, T.
    HISTOPATHOLOGY, 2010, 57 : 92 - 92
  • [27] The role of galectin-3 in promotion of the inflammatory response
    Liu, Fu-Tong
    Hsu, Daniel K.
    DRUG NEWS & PERSPECTIVES, 2007, 20 (07) : 455 - 460
  • [28] MECHANISM OF GALECTIN-3 BINDING BY BELAPECTIN, A GALECTIN-3 INHIBITOR DEVELOPED FOR NASH CIRRHOSIS
    Boudes, Pol F.
    Zoemer, Eli
    Shlevin, Harold
    HEPATOLOGY, 2021, 74 : 1144A - 1145A
  • [29] On the role of galectin-3 in cancer apoptosis
    Nakahara, S
    Oka, N
    Raz, A
    APOPTOSIS, 2005, 10 (02) : 267 - 275
  • [30] On the role of galectin-3 in cancer metastasis
    Raz, Avraham
    GLYCOBIOLOGY, 2006, 16 (11) : 1112 - 1112